The KCC3 cotransporter as a therapeutic target for peripheral neuropathy

Eric Delpire; Kristopher T Kahle

doi:10.1080/14728222.2017.1275569

The KCC3 cotransporter as a therapeutic target for peripheral neuropathy

Expert Opin Ther Targets. 2017 Feb;21(2):113-116. doi: 10.1080/14728222.2017.1275569. Epub 2017 Jan 5.

Authors

Eric Delpire¹, Kristopher T Kahle²

Affiliations

¹ a Departments of Anesthesiology , Molecular Physiology & Biophysics, and Brain Institute, Vanderbilt University School of Medicine , Nashville , TN , USA.
² b Departments of Neurosurgery , Pediatrics and Cellular & Molecular Physiology; and Centers for Mendelian Genomics, Yale School of Medicine , New Haven , CT , USA.

PMID: 28019725
DOI: 10.1080/14728222.2017.1275569

No abstract available

Keywords: Bumetanide; KCC2; KCC3; KCl cotransporter; NKCC1; Na-K-2Cl cotransporter; SPAK/OSR1; WNK; cell swelling; cell volume regulation; furosemide.

Publication types

Editorial
Research Support, N.I.H., Extramural

MeSH terms

Animals
Humans
Mice
Peripheral Nervous System Diseases / drug therapy
Peripheral Nervous System Diseases / physiopathology*
Symporters / genetics
Symporters / metabolism*

Substances

SLC12A6 protein, human
Slc12a6 protein, mouse
Symporters

Publication types

MeSH terms

Substances

Grants and funding